Premium / Analysis: still on the acquisition trail, should Kerry Logistics be eyeing Clipper and Wincanton?

first_img LOGIN Please Login New Premium subscriber REGISTER Hong Kong-based 3PL Kerry Logistics has plenty of dry powder left for further M&A activity, following a string of bolt-on deals in recent months (see here, here and here) – but is its management team up for the challenge?I would judge, based on recent events, that it is – but not everyone agrees.Feedback“Kerry management cannot see the wood for the trees,” a transport and logistics banker in London harshly stated this week, while another pointed to “positive ‘catalysts’ in its careful … Subscription required for Premium stories In order to view the entire article please login with a valid subscription below or register an account and subscribe to Premium Premium subscriber LOGIN Please either REGISTER or login below to continue << Go back Email* Reset Your Password By Alessandro Pasetti 25/01/2017 Forgotten your password? Please click here Email* Password* Resetlast_img read more

Control: Critical Consensus

first_imgControl: Critical ConsensusCritics rave as Remedy’s bizarre supernatural third-person shooter shows the studio “has reached its final form”Brendan SinclairManaging EditorMonday 26th August 2019Share this article Recommend Tweet ShareCompanies in this articleRemedy Entertainment”Control continues the basic formula that Remedy Entertainment has been playing with for all these years — third-person action with a hint of unreality — but it feels like the studio has reached its final form.”That’s a snippet of Mike Williams’ summary paragraph from his USgamer review of Control, which he gave four out of five stars. While the “final form” phrasing was distinctly his own, the sentiment behind it was one we saw repeatedly while surveying the assortment of reviews published Monday for Control.Like the studio’s Alan Wake and Quantum Break, Control has an ambitious narrative bent that sets it apart from the AAA crowd, even if the gameplay tends to rest on some tried-and-true concepts.In Control, players take the role of Jesse Faden, the newest employee of the Federal Bureau of Control, a government agency focused on the supernatural. The FBC’s office is The Oldest House, an impossible building whose layout and obedience to basic laws of physics are frequently shifting. But no sooner has Faden entered the scene than everything at The Oldest House goes haywire — more so than usual — and she tries her best to survive the chaos and make sense of the situation, often through third-person shooter combat.As Edwin Evans-Thirlwell wrote in Video Games Chronicle’s 4 out of 5 stars review, “Stewed in a fondness for eerie Americana built up through games like Max Payne and Alan Wake, it can be triumphantly bizarre. But so much of the game’s design, and so much of Jesse’s purpose within its story, is about reining in the concept and reducing everything to the cleanness and clearness of a third-person shooter.”Christian Donlan supported that assessment in giving the game a “Recommended” nod from Eurogamer, calling it “an obligingly straight-ahead blaster mounted in the most ornate of frames.”For some reviewers, this was a mark against the game. In reviewing the game for The Verge, Andrew Webster said the game’s reliance on cover-based shooter tropes can make it drag.”The problem is that the game relies too much on combat,” Webster said. “Often, enemies would respawn seemingly at random, and I’d be forced to replay simple but tedious combat scenarios multiple times. This discouraged exploration. You can get around the battles somewhat with Control’s fast-travel feature, though, of course, that isn’t really exploring at all. Worse still are some of the boss-like battles, which seem downright unfair, throwing wave after wave of bad guys at you. It’s a frustrating way to slow your progress, and there were times – particularly one egregiously long battle toward the end of the game – where I almost gave up on Control because I didn’t want to replay the same fight for the dozenth time.”Even so, Webster stressed “it’s worth pushing through to see the uniquely uncomfortable world Remedy has created.”Other reviewers had fewer misgivings about the combat. In an 8.8 out of 10 review for IGN, Jonathon Dornbush praised the psychic combat abilities that are a key part of the game’s fighting, in particular a telekinetic ability called “Launch” that lets players pummel enemies with anything in the environment not nailed down.”While it’s not quite the same level of tactile satisfaction as Kratos’ Leviathan axe in God of War, the oomph of hurling heavy objects around with my mind is as close as I’ve felt since,” Dornbush said.Reviewers loved the Launch abilityAnd even though Donlan had had plenty of praise for the Launch ability (and the joy of eliminating enemies by throwing armchairs, photocopiers, and various bits of old, heavy technology at them), he acknowledged how the straight-forward nature of the combat stands in contrast to the story.”There’s a little trickery in the narrative some of the time, but Control refuses to descend into all-out mechanical weirdness for the most part. It never forgets the pleasure of being a shooter above all other things, and with a few exceptions it’s more eager to hit you full-on with architectural beauty than warp your brain with the kind of spatial shenanigans you get in something like Portal.”A number of reviewers also noted the game’s somewhat open structure, where backtracking is required and new abilities will help open up previously inaccessible parts of The Oldest House.Related JobsSenior Game Designer – UE4 – AAA United Kingdom Amiqus GamesProgrammer – REMOTE – work with industry veterans! North West Amiqus GamesJunior Video Editor – GLOBAL publisher United Kingdom Amiqus GamesDiscover more jobs in games “This isn’t the kind of experience that pushes you in any one particular direction,” Webster said. “There are no big glowing arrows showing you where to go and the mini-map is pretty hard to use. I found myself getting lost a lot, particularly early on, as I stumbled through the confusingly maze-like structure of the Oldest House. But it also felt appropriate. At the beginning, Jesse is a newcomer to this world… You learn alongside her, and it’s very rewarding.”GameSpot’s Peter Brown said that structure also helps give the game a bit of longevity in his 8 out of 10 review, as Remedy filled Control with side quests and things that could be easily missed on an initial playthrough. What’s more, the world Remedy created makes those extra bits more than just busywork.”It’s not often that a game invades my thoughts the way Control has,” Brown said. “I’m at the point where I want to consume every last thing it has to offer. And if I’m honest, it also makes me want to go back and replay Remedy’s past games, too. Sure, it’s a faulty Metroidvania in some respects, but there are so many exceptional qualities afoot that Control handily deflects any momentary ire. I can’t wait to take part in discussions about the game, to see what others have figured out, and to better understand where it all fits into Jesse’s story.”Celebrating employer excellence in the video games industry8th July 2021Submit your company Sign up for The Daily Update and get the best of in your inbox. Enter your email addressMore storiesBeyond Control: What’s next for Remedy?CEO Tero Virtala on Vanguard, the shared universe of the Epic-funded games and why two million sales still doesn’t class Control as a major hitBy James Batchelor 2 months agoRecord year for Remedy despite no new game releasesOngoing success of Control boosts Finnish developer as it ramps up work on next game and two Epic-funded projectsBy James Batchelor 2 months agoLatest comments Sign in to contributeEmail addressPasswordSign in Need an account? Register now.last_img read more

Coakleys banned from registering local services for one year

first_imgIn granting a six-vehicle national licence to father and son Edward Constantine Coakley and Edward Neil Coakley, after revoking the six-vehicle national licence held by the family’s firm, Mackenzie Bus, Traffic Commissioner (TC) Joan Aitken has banned the partnership from registering any local services for a year. The implementation of the revocation of the company’s licence was delayed for two months solely to allow for alternative arrangements to be made for passengers who used the company’s registered local services.The firm, whose sole Director was Clare Coakley, and the partners had been called before the TC at an Edinburgh Public Inquiry. In 2017 the five-vehicle licence held by Mackenzie Bus No. 2 was revoked by the TC and an application by Coakley Brothers (Scotland), trading as ARC Travel, was refused by the TC both on financial grounds [routeone/Court Report/9 August 2017].The TC revoked the licence held by Mackenzie Bus on grounds of lack of financial standing and material change.In granting the partnership licence the TC made it subject to the condition preventing the partnership from registering local services for at least one year because of the level of timetable non-compliance in relation to the local services operated by Mackenzie Bus licence and Edward Constantine Coakley’s involvement in the management of the services.last_img read more

Central Vermont Medical Center earns an ‘A’ in patient safety

first_imgCentral Vermont Medical Center,Central Vermont Medical Center was recognized with an ‘A’Hospital Safety Score by The Leapfrog Group, an independent national nonprofit run by employers and other large purchasers of health benefits. The A score was awarded in the latest update to the Hospital Safety ScoreSM, the A, B, C, D or F scores assigned to U.S. hospitals based on preventable medical errors, injuries accidents, and infections. The Hospital Safety Score was compiled under the guidance of the nation’s leading experts on patient safety. The first and only hospital safety rating to be peer-reviewed in the Journal of Patient Safety (April 2013), Hospital Safety Score is designed to give the public information they can use to protect themselves and their families. ‘We are proud of the safety measures employed throughout our organization. It’s something our employees work hard at every day. We are honored to receive national recognition for their work,’noted CVMC president and CEO Judy Tartaglia.  ‘Earning an ‘A’on the Hospital Safety Score demonstrates that this hospital has exhibited excellence in our national database of patient safety measures,’said Leah Binder, President and CEO of The Leapfrog Group. ‘I’d like to congratulate CVMC for your achievements and encourage you to continue to put a priority on the safety of your patients.’ To see CVMC’‘s scores as they compare nationally and locally, visit the Hospital Safety Score website at is external), which provides information on how the public can protect themselves and loved ones during a hospital stay. Local hospitals’scores are also available on the free mobile app, available at is external).  CVMC is one of only two hospitals in Vermont to receive an ‘A’rating.  Calculated under the guidance of The Leapfrog Group’s eight-member Blue Ribbon Expert Panel, the Hospital Safety Score uses 26 measures of publicly available hospital safety data to produce a single score representing a hospital’s overall capacity to keep patients safe from infections, injuries, and medical and medication errors. The panel includes: John Birkmeyer (University of Michigan), Ashish Jha (Harvard University), Arnold Millstein (Stanford University), Peter Pronovost (Johns Hopkins University), Patrick Romano (University of California, Davis), Sara Singer (Harvard University), Tim Vogus (Vanderbilt University), and Robert Wachter (University of California, San Francisco).  About The Leapfrog GroupThe Leapfrog Group ( is external)) is a national nonprofit organization using the collective leverage of large purchasers of health care to initiate breakthrough improvements in the safety, quality and affordability of health care for Americans. The flagship Leapfrog Hospital Survey allows purchasers to structure their contracts and purchasing to reward the highest performing hospitals. The Leapfrog Group was founded in November 2000 with support from the Business Roundtable and national funders, and is now independently operated with support from its purchaser and other members.last_img read more

Proposed firewood quarantine rule available for public comment

first_imgVermont Business Magazine A proposed Rule Governing the Importation of Untreated Firewood into the State of Vermont has been filed with the Secretary of State. The purpose of the rule is to protect forest health by slowing the long-distance movement of wood-borne invasive forest pests, such as Asian longhorned beetle and emerald ash borer, and preventing the spread of pests into Vermont. The enabling legislation requires the Department of Forests, Parks, and Recreation to adopt regulations on importing untreated firewood.The proposed rule, as filed, is open for public comment until January 15, 2016. Two public hearings are scheduled:•        Tuesday, January 5th at the Manchester Town Hall in Manchester Center•        Thursday, January 7th at the Northeastern Vermont Regional Hospital in St. Johnsbury.Both hearings will begin at 4:00 PM.The proposed rule prohibits the importation of untreated firewood into Vermont. The definition of firewood states that it is wood processed for burning and less than 48 inches in length, but does not include wood chips, pellets, pulpwood, or wood for manufacturing purposes. It allows treated firewood to enter the state if it is treated to the USDA standard of 160° F (71.1° C) for at least 75 minutes at a certified treatment facility and is accompanied by certification of treatment. By written request, the Commissioner of Forests, Parks & Recreation may waive this prohibition under conditions which ensure that the firewood poses minimal threat to forest health. Violations may result in confiscation of firewood and/or a civil citation. The rules are to take effect onMay 1, 2016.For more information on the quarantine and the scheduled hearings, visit: is external).last_img read more

Remdesivir of scant benefit in hospitalized COVID patients, study finds

first_imgThe antiviral drug remdesivir had little effect in patients with moderate COVID-19 in 105 hospitals in the United States, Europe, and Asia in a randomized, controlled, open-label trial published late last week in JAMA, adding to a mixed picture of the drug in randomized clinical trials (RCTs), which are considered the gold standard for gauging interventions.Researchers compared the clinical status of 533 coronavirus patients who had moderate pneumonia and were randomly assigned to receive remdesivir for 5 or 10 days or standard care from Mar 15 to Apr 18. Remdesivir was given in a 200-milligram (mg) intravenous dose on the first day, followed by 100 mg a day.After 11 days of treatment, patients in the group receiving remdesivir for 5 days had significantly higher odds of clinical improvement on a 7-point ordinal scale than those in the standard-care group (odds ratio [OR], 1.65; 95% confidence interval [CI], 1.09 to 2.48; P = 0.02). But clinical status was not significantly different between the 10-day remdesivir group and the standard-care group (P = 0.18).Kaplan-Meier estimates of death from any cause at 28 days of treatment were 1% (95% CI, 0.0% to 2.6%) in the 5-day remdesivir group (log-rank P = 0.43 vs standard care), 2% (95% CI, 0.0% to 3.6%) in the 10-day remdesivir group (log-rank P = 0.72 vs standard care), and 2% (95% CI, 0.1% to 4.1%) in the group receiving standard care.Adverse events, clinical outcomesAny differences between the groups receiving remdesivir versus standard care in duration of supplemental oxygen or hospitalization were not significant.Adverse events occurred in 51% of patients in the 5-day remdesivir group, 59% in the 10-day remdesivir group, and 47% in the standard-care group. Nausea was more common in the groups receiving remdesivir than in those receiving standard care (10% vs 3%), as were low blood potassium levels (6% vs 2%) and headache (5% vs 3%).Nine patients had died by day 28, including 4 in the standard-care group, 3 in the 10-day remdesivir group, and 2 in the 5-day remdesivir group. All deaths occurred in patients 64 and older, and none were attributed to remdesivir therapy.Median patient age was 57 years, 39% were women, 56% had cardiovascular disease, 42% had high blood pressure, 40% had diabetes, and 14% had asthma. Median length of remdesivir therapy was 5 days for patients in the 5-day group and 6 days for those in the 10-day group. (Patients who improved enough to be released from the hospital didn’t finish their treatment course.)”Among patients with moderate COVID-19, those randomized to a 10-day course of remdesivir did not have a statistically significant difference in clinical status compared with standard care at 11 days after initiation of treatment,” the authors wrote. “Patients randomized to a 5-day course of remdesivir had a statistically significant difference in clinical status compared with standard care, but the difference was of uncertain clinical importance.”Perplexingly different study outcomesManufactured by Gilead Sciences, remdesivir was granted Emergency Use Authorization by the US Food and Drug Administration for patients 12 years and older with severe COVID-19 on May 20.Two RCTs at that time had compared clinical benefit of a 10-day course of remdesivir with a placebo. The first trial, conducted in Wuhan, China, didn’t find a benefit but had enrolled only 237 patients and may have been underpowered.The second, a US National Institutes of Health study involving 1,063 patients found that patients given remdesivir for 10 days recovered 4 days sooner than those given a placebo, but there was no significant difference in death rate between those who received remdesivir (7.1%) or placebo (11.9%) (hazard ratio, 0.70; 95% CI, 0.47 to 1.04). The current JAMA study was a continuation of that trial.In a JAMA commentary that accompanied the current study, Erin McCreary, PharmD, and Derek Angus, MD, MPH, of the University of Pittsburgh School of Medicine said that the different results of the three RCTs could be partially attributed to study design. They added that future studies should address which patients could benefit the most from remdesivir, how long they should receive it, how they will benefit, and what the relative benefit is in patients who also receive dexamethasone or other corticosteroids.”Some of the RCT findings suggest remdesivir could improve recovery for many millions of individuals around the world who may be hospitalized with COVID-19,” McCreary and Angus wrote. “However, the costs to produce and distribute remdesivir at such scale are considerable, and, most importantly, whether remdesivir offers incremental benefit over corticosteroids, which are widely available and inexpensive, is unknown.” Small study of severe COVID shows promiseIn contrast with the JAMA study, the Journal of Antimicrobial Chemotherapy yesterday published a small retrospective, observational study in Italy that found that remdesivir may have benefitted COVID-19 patients receiving mechanical ventilation.Of 51 COVID-19 patients receiving mechanical ventilation at Pesaro hospital from Feb 29 and Mar 20, 25 received 200 mg of intravenous remdesivir for compassionate use on the first day, followed by 100 mg daily on days 2 to 10. Most patients also received other investigational treatments for the coronavirus, such as hydroxychloroquine (64.7%), lopinavir/ritonavir (56.9%), and tocilizumab (17.6%). Twenty-five patients also required dialysis.The antiviral drug was associated with improved survival (OR, 3.51; 95% CI, 1.77 to 6.95; P < 0.001), and Kaplan-Meier curves demonstrated significantly lower death rates in patients who received remdesivir (56% vs 92%; P < 0.001).The most common underlying conditions were high blood pressure (54.9%), diabetes (13.7%), ischemic heart disease (13.7%), and moderate kidney failure (7.8%).Twenty patients completed 10 days of remdesivir treatment, and five (20%) died of COVID-19 infection at a median of 5 days after starting therapy. At final follow-up, 38 patients (74.5%) had died, 9 (17.6%) had been released from the hospital, and 4 (7.8%) remained hospitalized but no longer needed mechanical ventilation.The authors noted that the study period came at the beginning of the pandemic, when the demand for intensive care unit resources such as ventilators, doctors, and specialized nurses far outstripped the supply, so many patient needs went unmet."In conclusion, in this study the mortality rate of patients with COVID-19 under mechanical ventilation is confirmed to be high," they wrote. "The use of remdesivir was associated with a significant beneficial effect on survival."Observational studies like this one are less valuable than RCTs in assessing a drug and, in fact—as opposed to RCTs—cannot prove that remdesivir actually was the cause of the improved results.last_img read more

Civil Air Patrol Marks 4th Straight Year Saving 100+ Lives

first_imgThe Civil Air Patrol marked its 100th and 101st save Aug. 4, when CAP’s National Cell Phone Forensics Team provided a high-priority area to focus search efforts for two lost hikers. Courtesy/Civil Air Patrol CIVIL AIR PATROL News:MAXWELL AIR FORCE BASE, Ala. – For the fourth consecutive fiscal year, Civil Air Patrol has passed the century mark in lives saved, as credited by the Air Force Rescue Coordination Center.CAP, the official auxiliary of the U.S. Air Force, conducts approximately 90 percent of all search operations within the United States as assigned by the AFRCC.The 100th and 101st save occurred Aug. 4, when CAP’s National Cell Phone Forensics Team provided the Wyoming Joint Operations Center with a high-priority area to focus search efforts for two lost hikers in Big Horn County. Using cell phone forensic information gathered by the team early that morning, local searchers found the hikers alive and returned them to safety later in the morning.“And with that, we moved to 101 lives saved to date in fiscal year 2020,” said John Desmarais, CAP’s director of operations, who said the two saves related to cell phone forensics were typical of most of those credited to CAP in recent years. “More than 90 percent of our saves occur with the support of the cell phone team using technology that Civil Air patrol created using source data provided cellular carriers.”CAP totaled 158 saves in fiscal 2018, a new record for lives saved in a fiscal year. In 2019 and 2017, CAP was credited with 117  and 110 saves, respectively, by the AFRCC.“What especially makes Civil Air Patrol a strong Total Force partner is how they complement the efforts of the other partners to serve our country,” said Maj. Gen. Bryan Radliff, reserve advisor to the commander, First Air Force, Air Forces Northern. “Closely aligning resources to the mission requirements and maintaining operational readiness — even during the COVID pandemic — is something we rely on and CAP delivers.”Desmarais said the 100-plus saves trend over the past four years reflects CAP’s continuous advances in technology and training in one of the Air Force auxiliary’s primary missions — emergency services.Since its inception in late 1941, Civil Air Patrol has traditionally performed search and rescue missions by operating the world’s largest fleet of single engine piston-powered aircraft to search for missing people and overdue aircraft. More recently, it is CAP’s innovative technology, like cell phone forensics and radar analysis, that have enabled the organization to be even more efficient. Saves resulted from a wide variety of search scenarios that included plane crash survivors, missing persons, lost or injured hikers in remote locations, stranded boaters offshore, and more.“Our technology has evolved as we have adapted and developed our tools and our training to make performing search and rescue and other emergency services missions more efficient,” Desmarais said. “Leveraging tools like cellphone forensics and radar analysis make it faster and easier to help find people and planes, even in situations where it is not possible to launch one of our aircraft due to poor flying conditions, remote locations or other factors.”Saving lives never gets old, as every successful CAP search and rescue mission is celebrated with an alert from Desmarais to the organization’s national command team.The alerts always elicit a response from members of the team, as was the case following this past week’s rescue in Wyoming, “This is outstanding in every way,” said Chief Master Sgt. Robert M. Dandridge, CAP’s national command chief. “Over a hundred saved lives and counting … with many thankful and happy families reunited. Great outcome, CAP.”About Civil Air PatrolEstablished in 1941, Civil Air Patrol is the official auxiliary of the U.S. Air Force and as such is a member of its Total Force. In its auxiliary role, CAP operates a fleet of 560 single-engine Cessna aircraft and 1,550 small Unmanned Aircraft Systems (sUAS) and performs about 90% of continental U.S. inland search and rescue missions as tasked by the Air Force Rescue Coordination Center. Often using innovative cellphone forensics and radar analysis software, CAP was credited by the AFRCC with saving 110 lives in fiscal 2019. CAP’s 66,000 members also perform homeland security, disaster relief and drug interdiction missions at the request of federal, state and local agencies. As a nonprofit organization, CAP plays a leading role in aerospace education using national academic standards-based STEM (science, technology, engineering and math) education. Members also serve as mentors to over 28,000 young people participating in CAP’s Cadet Programs. One of the premier public service organizations in America, CAP benefits the nation with an estimated economic impact of $209 million annually. Visit www.CAP.News or for more information.last_img read more

Chart 163: COVID-19 In New Mexico Aug. 24

first_imgOverall COVID-19 risk by state. The nonprofit organization Covid Act Now monitors daily diagnoses, infection rates, testing positivity, ICU headroom, and contacts traced in each state. The overall COVID-19 risk is based on these five metrics. map/ Source: Created by Eli Ben-Naimlast_img

The industry’s World Cup predictions

first_imgTo access this article REGISTER NOWWould you like print copies, app and digital replica access too? SUBSCRIBE for as little as £5 per week. Would you like to read more?Register for free to finish this article.Sign up now for the following benefits:Four FREE articles of your choice per monthBreaking news, comment and analysis from industry experts as it happensChoose from our portfolio of email newsletterslast_img

‘Midway’ storms past ‘Doctor Sleep’ to top the box office with $17.5 million

first_imgReiner Bajo(NEW YORK) — Midway, the drama based on the true story of the titular World War II Battle from Independence Day director Roland Emmerich, pulled off a huge upset this weekend, topping the weekend box office by beating Stephen King’s Doctor Sleep, which was favored to win the weekend.Midway, starring Woody Harrelson, Luke Evans, Patrick Wilson, Mandy Moore, Dennis Quaid, Aaron Eckhart and Nick Jonas, beat expectations, delivering an estimated $17.5 million.  That number should swell to around $20 million with the Veterans Day holiday factored in on Monday.In second place was Doctor Sleep. The sequel to The Shining, starring Ewan McGregor, pulled in an estimated $14.1 million — way below the $25 million it was expected to deliver.Playing with Fire, which debuted this weekend, also topped expectations, collecting an estimated $12.8 million, for a third place finish.  The family comedy, starring John Cena, Keegan-Michael Key and John Leguizamo, took in $2 million more than predicted.Fourth place belonged to this week’s fourth major release, the holiday rom-com Last Christmas.  Led by Game of Thrones‘ Emilia Clarke and Crazy Rich Asians‘ Henry Golding, the film from Bridesmaids director Paul Feig earned an estimated $11.6 million.Rounding out the top five was Terminator: Dark Fate, delivering an estimated $10.8 million in its second week of release.Finishing just outside the top five at number 6 was Joker, in its sixth week of release.  The film, spotlighting the classic Batman villain, is now just $15 million shy of reaching the $1 billion mark worldwide.  Once it does, it will become the fourth DC Comics adaptation to accomplish that, joining Aquaman, The Dark Knight Rises and The Dark Knight.In limited release, Honey Boy, Shia LeBeouf’s semi-autobiographical drama, had an impressive opening, earning an estimated $288,825 from just four theaters.Here are the top 10 movies Friday through Sunday, with estimated domestic box office earnings:1. Midway, $17.5 million2. Doctor Sleep, $14.1 million3. Playing With Fire, $12.8 million4. Last Christmas, $11.6 million5. Terminator: Dark Fate, $10.8 million6. Joker, $9.2 million7. Maleficent: Mistress of Evil, $8 million8. Harriet, $7.2 million9. Zombieland 2: Double Tap, $4.3 million10. The Addams Family, $4.2 millionCopyright © 2019, ABC Audio. All rights reserved.last_img read more